Meropenem
- Generic Name
- Meropenem
- Brand Names
- Vabomere
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O5S
- CAS Number
- 96036-03-2
- Unique Ingredient Identifier
- YOP6PX0BAO
- Background
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
...
- Indication
For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, vi...
- Associated Conditions
- Bacterial Infections, Complicated Intra-Abdominal Infections (cIAIs), Meningitis, Bacterial, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin infection bacterial
- Associated Therapies
- -
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
- Conditions
- Interventions
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2018-11-16
- Target Recruit Count
- 494
- Registration Number
- NCT01445678
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
- Conditions
- Interventions
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Joseph Kuti
- Target Recruit Count
- 30
- Registration Number
- NCT01429259
- Locations
- 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
GSK2251052 in the Treatment of Complicated Intra-abdominal Infections
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT01381562
- Locations
- 🇪🇸
GSK Investigational Site, Pama de Mallorca, Spain
Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)
- Conditions
- Interventions
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2016-02-03
- Target Recruit Count
- 232
- Registration Number
- NCT01292031
- Locations
- 🇬🇷
Sotiria Hospital, Medical School University of Athens, Athens, Greece
🇬🇷General Hospital of Larissa, Thessalia University, Athens, Greece
🇮🇹AO Ospedale Niguarda Ca Granda Milano, Milan, Italy
A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT01110382
Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
- First Posted Date
- 2010-01-08
- Last Posted Date
- 2010-04-13
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 240
- Registration Number
- NCT01044719
- Locations
- 🇬🇧
Department of Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom
Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
- Conditions
- Interventions
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 204
- Registration Number
- NCT00752219
- Locations
- 🇺🇸
Cedars-Sinai Medical Center Dept of Surgery, Los Angeles, California, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections
- Conditions
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- The Emmes Company, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00621192
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Magee Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Complicated Skin and Skin Structure Infections
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1000
- Registration Number
- NCT00619710
A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 750
- Registration Number
- NCT00579956
- Locations
- 🇹🇭
Sappasithiprasong Hospital, Ubonratchathani, Ubon, Thailand
🇹🇭Udon Thani General Hospital, Udon Thani, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.